Muhlenbeck et al., 1998). These discrepancies could high levels of TRAIL upregulation and enhanced cytobe due to differences in cell lines or cell type-specific kine production in TRAIL-R Ϫ/Ϫ cells. The immediatesignaling. However, the similarity to TNF receptor signalearly TLR signaling events in TRAIL-R Ϫ/Ϫ macrophages ing has led to speculation that sensitivity to TRAIL inand dendritic cells are normal, but IB-␣ homeostatic duced apoptosis may be regulated by expression of regulation and NF-B activity at later time points is antiapoptotic factors downstream of NF-B or by more perturbed. These data suggest that TRAIL-R negaproximal factors such as c-FLIP, which inhibits castively regulates innate immune responses. as defects in negative selection, although this latter find- Figure 1F ). Western blot analysis with a TRAIL-R-specific polyclonal antibody showed that algenes, Salmonella typhimurium, encephalomyocarditis virus (EMCV), Mycobacterium bovis Bacillus Calmettethough the wild-type construct produced TRAIL-R protein at the expected size, no protein was generated by Gué rin (BCG), and murine cytomegalovirus (MCMV). TRAIL-R-deficient cells were also treated ex vivo with the mutant construct ( Figure 1G ). These data demonstrated that our targeted allele is indeed a null mutation. several TLR stimuli. We found that loss of TRAIL-R does not affect responses to some challenges but led to enTo remove neomycin from the gene locus, TRAIL-R ϩ/Ϫ mice were crossed to CMV-Cre transgenic animals hanced resistance against MCMV challenge and increased cytokine production in BCG-infected macro-(Nagy et al., 1998). No differences between animals with or without the neomycin cassette were observed, and phages. In addition, macrophages and dendritic cells lacking TRAIL-R had increased cytokine responses after an identical mutant transcript was produced by the neomycin-deleted locus (data not shown). ex vivo treatment with some TLR stimuli. These data suggest that TRAIL-R is an important negative regulator of the cytokine responses of the innate immune system. We next examined the effects of TRAIL-R deficiency on the macrophage response to LPS or BCG stimulation. ligands ( Figure 4B ). TRAIL-R levels were not significantly changed after any of these treatments ( Figure 4C and After exposure to LPS or BCG, macrophages secrete TNF␣. We examined production of TNF␣ by intracellular data not shown). (A) Bone marrow-derived macrophages (top) and dendritic cells (bottom) from TRAIL-R Ϫ/Ϫ and wild-type littermate controls were treated with 1 g/ml LPS (macrophages) or 100 ng/ml LPS (dendritic cells) for the indicated time points. Cell lysates were used for Western blot analysis with antibodies specific for total (IB-␣) or phosphorylated IB-␣ (P-IB-␣), phosphorylated JNK (P-JNK), or phosphorylated p38 (P-p38). As a loading control, antibodies for total p38 (macrophage) or total ERK1/2 (DC) were used. The experiments have been done more than three times with similar results. (B) Bone marrow-derived macrophages from TRAIL-R Ϫ/Ϫ and wild-type littermate controls were treated with 50ng/ml LPS and nuclear extracts were generated and analyzed by EMSA for NFB activity as described in the materials and methods. EMSA for the GT box was performed as a loading control. In summary, the data presented here define a role for may explain the difference between the results of our TRAIL-R signaling independent of its ability to initiate EMCV infection of TRAIL-R knockout animals compared apoptosis in sensitive cells. By using mice deficient for to other studies using anti-TRAIL antibodies. It is inter-TRAIL-R, we have shown that TRAIL-R signaling contribesting to speculate that in certain situations, the TRAIL utes to the negative regulation of cytokine production decoy receptors could act as "ligands" to signal through in macrophages and dendritic cells in the context of the membrane bound TRAIL "receptor. by surface activation markers) and suggests that TRAIL-R signaling is primarily repressive for cytokine production.
ing is controversial (Cretney et al., 2003) . These data introducing a frame shift and an early stop codon within exon 7 ( Figure 1E ). The resulting predicted protein consuggest that TRAIL may play roles in tumor surveillance, regulation of autoimmunity, and T cell development.
tains most of the extracellular domain of the TRAIL-R but lacks a transmembrane domain or any of the cytoWe have now generated a mouse line deficient for the TRAIL receptor. These mice appear to develop normally plasmic tail. To determine if a stable protein could be encoded by this mutant sequence, constructs conwith an intact immune system. In contrast to one study using TRAIL Ϫ/Ϫ mice (Lamhamedi-Cherradi et al., 2003) taining the coding region from either the wild-type or mutant TRAIL-R transcripts were transfected into 293T but consistent with another report (Cretney et al., 2003) using the same line of TRAIL Ϫ/Ϫ mice, we found no decells. Consistent with the endogenous TRAIL-R transcript levels, Northern blot analysis showed lower mRNA fects in thymic negative selection in the absence of TRAIL-R. To assess the role of TRAIL-R in immune reexpression of the mutant transcript in transfected cells compared to the level of the wild-type transcript in transsponses, we challenged TRAIL-R Ϫ/Ϫ mice and cells with a variety of pathogens, including Listeria monocytofected cells ( Figure 1F ). Western blot analysis with a TRAIL-R-specific polyclonal antibody showed that algenes, Salmonella typhimurium, encephalomyocarditis virus (EMCV), Mycobacterium bovis Bacillus Calmettethough the wild-type construct produced TRAIL-R protein at the expected size, no protein was generated by Gué rin (BCG), and murine cytomegalovirus (MCMV). TRAIL-R-deficient cells were also treated ex vivo with the mutant construct ( Figure 1G ). These data demonstrated that our targeted allele is indeed a null mutation. several TLR stimuli. We found that loss of TRAIL-R does not affect responses to some challenges but led to enTo remove neomycin from the gene locus, TRAIL-R ϩ/Ϫ mice were crossed to CMV-Cre transgenic animals hanced resistance against MCMV challenge and increased cytokine production in BCG-infected macro-(Nagy et al., 1998). No differences between animals with or without the neomycin cassette were observed, and phages. In addition, macrophages and dendritic cells lacking TRAIL-R had increased cytokine responses after an identical mutant transcript was produced by the neomycin-deleted locus (data not shown). ex vivo treatment with some TLR stimuli. These data suggest that TRAIL-R is an important negative regulator of the cytokine responses of the innate immune system. . TRAIL Ϫ/Ϫ animals were reported to exhibit defective negtaining the desired homologous recombination were identified by Southern blot analysis using 5Ј and 3Ј ative selection by one group, and blocking TRAIL function by soluble DR5 protein was found to enhance antiprobes and were then used to generate TRAIL-R heterozygous mice ( Figure 1B Figure S1B) . To deterTherefore, RT-PCR analysis was performed to determine if the TRAIL-R was indeed absent in TRAIL-R Ϫ/Ϫ mine if superantigen-induced negative selection was defective in our TRAIL-R Ϫ/Ϫ animals, we backcrossed mice. Analysis of transcripts from multiple tissues using oligonucleotides spanning the region between exons 4 the TRAIL-R null allele onto the Balb/c background for four generations and examined mammary tumor virus and 6 showed a band in TRAIL-R wild-type, but not knockout, animals ( Figure 1C ). To further ensure we did (Mtv)-induced negative selection. Balb/c strain of mice are I-E d and carry Mtv-9, which encodes an endogenous not have a truncated but functional transcript, we designed primers to amplify the entire TRAIL-R transcript.
Normal Lymphocyte Populations and Negative Selection in TRAIL-R
superantigen capable of deleting V ␤ 3-, V ␤ 5-, and V ␤ 11-expressing T cells during negative selection (Tomonari RT-PCR analysis with these TRAIL-R-specific oligonucleotides showed a truncated transcript in all tissues et al. , 1993; Woodland et al., 1991a Woodland et al., , 1991b . No differences were seen in the decrease of the frequencies of examined, including heart, kidney, and thymus ( Figure  1D We next examined the effects of TRAIL-R deficiency on the macrophage response to LPS or BCG stimulation. ligands ( Figure 4B ). TRAIL-R levels were not significantly changed after any of these treatments ( Figure 4C and After exposure to LPS or BCG, macrophages secrete TNF␣. We examined production of TNF␣ by intracellular data not shown). (A) Bone marrow-derived macrophages (top) and dendritic cells (bottom) from TRAIL-R Ϫ/Ϫ and wild-type littermate controls were treated with 1 g/ml LPS (macrophages) or 100 ng/ml LPS (dendritic cells) for the indicated time points. Cell lysates were used for Western blot analysis with antibodies specific for total (IB-␣) or phosphorylated IB-␣ (P-IB-␣), phosphorylated JNK (P-JNK), or phosphorylated p38 (P-p38). As a loading control, antibodies for total p38 (macrophage) or total ERK1/2 (DC) were used. The experiments have been done more than three times with similar results. (B) Bone marrow-derived macrophages from TRAIL-R Ϫ/Ϫ and wild-type littermate controls were treated with 50ng/ml LPS and nuclear extracts were generated and analyzed by EMSA for NFB activity as described in the materials and methods. EMSA for the GT box was performed as a loading control. with the delayed time course of TRAIL upregulation (4 hr (data not shown). Thus, TRAIL-R signaling most likely regulates IB-␣ degradation or stability, but not the tranpost LPS stimulation, see above) and suggest that TRAIL-R primarily impacts late signaling events downscription of IB-␣ after NF-B activation.
To assess the differences in NF-B transcriptional stream of Toll-like receptors. Similar findings were found in bone marrow-derived dendritic cells from TRAIL-R Ϫ/Ϫ activity in TRAIL-R wild-type and knockout macrophages, we performed gel shift assays by using the NFand wild-type littermates treated with LPS ( Figure 7A) . No difference in IB-␣ protein levels was observed be-B consensus sequence. As a control, the same nuclear extracts were incubated with GT box oligonucleotides, tween wild-type and knockout macrophages after TNF␣ stimulation (Supplemental Figure S4) In summary, the data presented here define a role for may explain the difference between the results of our TRAIL-R signaling independent of its ability to initiate EMCV infection of TRAIL-R knockout animals compared apoptosis in sensitive cells. By using mice deficient for to other studies using anti-TRAIL antibodies. It is inter-TRAIL-R, we have shown that TRAIL-R signaling contribesting to speculate that in certain situations, the TRAIL utes to the negative regulation of cytokine production decoy receptors could act as "ligands" to signal through in macrophages and dendritic cells in the context of the membrane bound TRAIL "receptor. by surface activation markers) and suggests that TRAIL-R signaling is primarily repressive for cytokine production.
